Resilience cuts 120 employees at a former bluebird gene therapy site
National Resilience is laying off 120 staffers from its gene therapy facility in North Carolina, only a month after the San Diego-headquartered CDMO shrunk its headcount in Florida. This latest round...
View ArticleGene editing startup Scribe Therapeutics cuts staff by 20%
Scribe Therapeutics, a biotech co-founded by CRISPR pioneer Jennifer Doudna, is reducing its workforce by about 20%, the company confirmed to Endpoints News. CEO Ben Oakes told Endpoints by phone...
View ArticleTranscarent buys health navigation incumbent Accolade for $621M
Unicorn startup Transcarent has bought up a publicly traded rival as it looks to expand as a health navigation giant in one of the first health tech deals of the year. Accolade shareholders will...
View ArticleAstellas stops developing autologous cell therapy for lymphoma
Astellas has ended work on a cell therapy that it was exploring for CD20-positive B cell lymphomas, the Japan-based pharma confirmed to Endpoints News on Wednesday. The pharma giant ended a
View ArticleAhead of adcomm, FDA discusses Seikagaku's mixed trial results for its lumbar...
Japan-based Seikagaku will face an FDA advisory committee on Friday, with the agency raising concerns ahead of the meeting regarding the efficacy of its condoliase injection for the treatment of...
View ArticlePfizer, GSK add risk of Guillain-Barré to RSV vaccine labels
Pfizer and GSK’s RSV vaccines have a new warning at the request of the FDA, relaying an increased risk of Guillain-Barré syndrome within the first 42 days post-vaccination. The agency said
View ArticleRevance weighs competing buyout offer amid push from original bidder
Revance Therapeutics said Wednesday it will have talks with Teoxane on its bid to take over Revance's company. But Crown Laboratories — the initial bidder — has made clear it won't wait much longer on...
View ArticleFirst-ever gene edit of infant boy leads to apparent cure
A baby boy born with a debilitating genetic disease will likely no longer require a liver transplant to stabilize his condition, thanks to a first-of-its-kind genetic medicine he got at 6 months of...
View ArticleMaaT Pharma touts ‘unprecedented’ Phase 3 efficacy of graft-versus-host...
French biotech MaaT Pharma says its acute graft-versus-host disease treatment exceeded expectations in a single-arm Phase 3 study in Europe. The company now intends to submit MaaT013 for regulatory...
View ArticleAiolos team reunites with $411M for new biotech with obesity drugs from China
There's a shopping bonanza for new obesity medicines going on among a marquee cohort of biopharma investors who are in-licensing treatment candidates from Chinese and European drug developers. Joining...
View ArticleH1 buys General Catalyst-backed Ribbon Health
H1 has bought Ribbon Health in one of the first health tech deals announced this year, the companies revealed Wednesday. The deal allows H1, an analytics company that connects doctors to organizations...
View ArticleCoave raises €32M Series A despite being two years away from the clinic
More than many other corporate VCs, Novo Holdings has the cash to take risks. Its most recent is co-leading the €32 million ($33 million) Series A financing of Coave Therapeutics, a gene therapy...
View ArticleLonza’s Synaffix adds Boehringer and Mitsubishi Tanabe as ADC licensing partners
Lonza’s Synaffix has secured two separate licensing deals with Boehringer Ingelheim and Japanese drugmaker Mitsubishi Tanabe Pharma for its antibody-drug conjugate tech. The two “long-term” deals were...
View ArticleLeyden Labs gets $70M to test if nasal sprays can help protect against viruses
A Dutch biotech creating nasal sprays to protect against the flu and coronavirus has raised an additional $70 million and acquired a nimble Singapore startup to help with its mission. Leiden-based...
View ArticleVersant unveils Light Horse with $62M and a partnership with Novartis
Versant Ventures' latest biotech emerged on Thursday morning with a $62 million Series A from Bristol Myers Squibb, AbbVie and others, plus a partnership with Novartis that could be worth as much as $1...
View ArticleNumab extends its Series C; AnaCardio raises $19M for its heart failure drug
Plus, news about RheumaGen and RyboDyn: Numab Therapeutics brings in $55M: The Swiss biotech extended its Series C, originally disclosed in ...
View ArticleSamsung Bio extends ADC partnership; Veeda rebrands as CDMO
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Samsung Biologics has extended its collaboration with LigaChem...
View ArticleIs this the digital health M&A wave we’ve been expecting?
2025 is starting out strong with a couple of deals. The most notable is a tie-up between Glen Tullman’s Transcarent and Accolade, the health navigation company that was part of the wave of digital...
View ArticleAfter lackluster 2024, biopharma industry prays stalled M&A will finally move...
Biopharma leaders will descend on San Francisco next week hopeful that the industry’s biggest dealmaking event will finally yield some much sought-after M&A. The industry needs it after a slow...
View ArticleCell therapy startup A2 Biotherapeutics nets $80M Series C
A2 Biotherapeutics has raised $80 million to run three experimental CAR-T programs for solid tumor cancers. The biotech is developing what it calls logic-gated cell therapies, which it believes will...
View Article